Company’s 36-month beta value is 2.31.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PTPI is 8.73M, and currently, short sellers hold a 3.38% ratio of that floaft. The average trading volume of PTPI on October 17, 2024 was 237.17K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PTPI) stock’s latest price update
The stock of Petros Pharmaceuticals Inc (NASDAQ: PTPI) has increased by 14.76 when compared to last closing price of 0.30.Despite this, the company has seen a gain of 10.00% in its stock price over the last five trading days. accesswire.com reported 2024-09-11 that Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussions NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) (“Petros” or the “Company”), a company focused on expanding consumer access to medication through over-the-counter (“OTC”) drug development programs, today announced results of an initial study to determine consumer comprehension of the messaging in its App Technology (“App Comp”), which has unique differences from the current Drug Facts Label (“DFL”). Of the 31 objectives, 29 scored >90% comprehension Point Estimate (“PE”), 30 scored >86.7% comprehension PE, and all scored > 80% comprehension PE.
PTPI’s Market Performance
Petros Pharmaceuticals Inc (PTPI) has seen a 10.00% rise in stock performance for the week, with a -8.79% decline in the past month and a -15.71% plunge in the past quarter. The volatility ratio for the week is 10.82%, and the volatility levels for the past 30 days are at 9.91% for PTPI. The simple moving average for the past 20 days is 2.62% for PTPI’s stock, with a -54.71% simple moving average for the past 200 days.
PTPI Trading at 1.57% from the 50-Day Moving Average
After a stumble in the market that brought PTPI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.59% of loss for the given period.
Volatility was left at 9.91%, however, over the last 30 days, the volatility rate increased by 10.82%, as shares sank -6.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.24% lower at present.
During the last 5 trading sessions, PTPI rose by +10.00%, which changed the moving average for the period of 200-days by -75.19% in comparison to the 20-day moving average, which settled at $0.3409. In addition, Petros Pharmaceuticals Inc saw -75.19% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PTPI
Current profitability levels for the company are sitting at:
- -3.9 for the present operating margin
- 0.53 for the gross margin
The net margin for Petros Pharmaceuticals Inc stands at -3.14. The total capital return value is set at -1.06. Equity return is now at value -91.54, with -33.16 for asset returns.
Based on Petros Pharmaceuticals Inc (PTPI), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at -1.15. The debt to equity ratio resting at 0.83. The interest coverage ratio of the stock is 1429.99.
Currently, EBITDA for the company is -7.35 million with net debt to EBITDA at -0.02. When we switch over and look at the enterprise to sales, we see a ratio of 0.86. The receivables turnover for the company is 2.32for trailing twelve months and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.40.
Conclusion
In a nutshell, Petros Pharmaceuticals Inc (PTPI) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
